- costing methods
- health outcomes
- evidence synthesis
- test performance
- value of information
- models and tools
- mathematical models
- state-transition
- dynamic transmission
- microsimulation
- calibration/validation
- dynamic simulation
- infectious diseases
- child/nutrition
- global governance
- business/industry
- climate/environment
- economics/finance
- global
Resources Repository
-
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Costing Methods | Health Outcomes | Economics/Finance | Global | Global Governance | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology -
ArticlePublication 2023Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines …
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines in 105 low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies, compared to a ‘no-new-vaccine’ counterfactual. Vaccine scenarios considered two vaccine product profiles (one targeted at infants, one at adolescents/adults), both assumed to prevent progression to active TB. Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden.…
Mathematical Models | Economics/Finance | Global | Infectious Diseases | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Costing Methods | Economics/Finance | Global | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Government/Law | Health/Medicine | Science/Technology -
Lesson/ModuleWeb Portal, Teaching Resource 2016Scientific Evidence of Factual Causation
This module examines three scientific areas that provide evidence bearing on causation in the “toxic …
This module examines three scientific areas that provide evidence bearing on causation in the “toxic tort” or environmental disease context: epidemiology, toxicology, and genetics. These scientific disciplines are used in civil lawsuits and in regulatory proceedings in which causation or risk is an issue. The module is appropriate for non-scientist law students as well as others interested in learning the science of toxic tort causation, including practicing attorneys, judges, and public policy and public health…
Evidence Synthesis | Climate/Environment | Global | Child/Nutrition | Risk Analysis | Chronic Disease/Risk | Environmental Health | Policy/Regulation | Food/Agriculture | Government/Law | Health/Medicine | Science/Technology | North America | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Quantitative Literacy -
ArticlePublication 2016Costs and Benefits of Integrated RMNCH
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, …
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, newborn and child health interventions in countries with high child and maternal mortality to demonstrate that very high returns can be achieved through this investment and to underscore the importance of an accurate assessment of those returns. This includes the full range of costs involved in delivering integrated care and the full range of benefits that flow from the interventions.…
Costing Methods | Economics/Finance | Global | Child/Nutrition | Priority Setting/Ethics | Maternal/Reproductive Health | Health Systems | Health/Medicine -
ArticlePublication 2016Using Top-Down and Bottom-Up Costing Approaches in LMICs
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel …
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel technologies in low-income and middle-income countries is a methodologically challenging and substantial empirical undertaking. Using the example of costing the scale-up of Xpert Mycobacterium tuberculosis (MTB)/resistance to riframpicin (RIF) in South Africa, the authors estimate costs, by applying two distinct approaches of bottom-up and top-down costing, together with an assessment of processes and capacity. The unit costs measured using the…
Costing Methods | Economics/Finance | Global | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems | Health/Medicine -
ReviewPublication 2014Valuing Vaccination
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps …
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with…
Costing Methods | Economics/Finance | Global | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Benefit-Cost Analysis | Health Systems | Health/Medicine -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Mathematical Models | Economics/Finance | Global | Infectious Diseases | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Science/Technology